Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449709
Status:
TERMINATED
Last Update Posted:
2012-03-19
First Post:
2007-03-19
Brief Title:
A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Two-part Open-label Cross-over Study to Assess the Pharmacokinetics of GSK221149 Following Single Oral Doses of Various Modified Release Formulations and a Solution in Healthy Adult Subjects
Status:
TERMINATED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PreTerm Labor prior to 37 weeks gestation is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability Oxytocin is a hormone produced by the body during labor GSK221149 is an experimental drug that will be used to block the effects of oxytocin and therefore pause or prevent contractions In this study the pharmacokinetics of various modified release formulations of GSK221149 will be investigated in healthy non-pregnant adult subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None